Compare RGP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RGP | NMRA |
|---|---|---|
| Founded | 1996 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.7M | 87.4M |
| IPO Year | 2000 | 2023 |
| Metric | RGP | NMRA |
|---|---|---|
| Price | $2.65 | $0.33 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $6.50 | $5.33 |
| AVG Volume (30 Days) | 261.7K | ★ 1.5M |
| Earning Date | 01-06-2027 | 11-16-2026 |
| Dividend Yield | ★ 10.41% | N/A |
| EPS Growth | ★ 79.14 | 5.23 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $452,006,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.33 | $0.32 |
| 52 Week High | $5.37 | $3.65 |
| Indicator | RGP | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 38.90 | 30.94 |
| Support Level | $2.58 | N/A |
| Resistance Level | $2.85 | $0.65 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 24.07 | 1.32 |
Resources Connection Inc is a professional services firm. Its segments include On-Demand Talent provides businesses with a go-to source for bringing in experts when its needed, serving the office of the CFO; Consulting drives transformation across people, processes and technology across domain areas including finance, technology and digital, risk and compliance and operational performance; Europe & Asia Pacific offers both on-demand and consulting services to clients throughout Europe and Asia Pacific; Outsourced Services; and Sitrick. It derives the majority of revenue from On-Demand Talent segment. Geographically, it operates in United States and internationally.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.